Snapshot from Aug 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Capricor Securities Class Action Lawsuit
Regulatory class action

Capricor Securities Class Action Lawsuit

Analysis based on 7 articles · First reported Aug 07, 2026 · Last updated Aug 22, 2026

Sentiment
-60
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The FDA's negative briefing documents and the subsequent securities class action lawsuit have severely damaged investor confidence in Paragon Therapeutics, causing a 64% stock price decline. The lawsuit and regulatory scrutiny may further pressure Capricor's stock and its ability to obtain FDA approval for Deramiocel.

Biotechnology Pharmaceuticals
Event Summary

Paragon Therapeutics, Inc. and certain executives face a securities class action lawsuit filed by Kahn Swick & Foti on behalf of investors who purchased Capricor securities between December 17, 2025 and July 26, 2026. The lawsuit alleges that Capricor failed to disclose material information regarding changes to the statistical analysis plan (SAP) for its lead product candidate, Deramiocel, prior to the FDA's advisory committee review. On July 27, 2026, the FDA published briefing documents that criticized Capricor's post-hoc SAP changes, leading to a 64% drop in Capricor's stock price to $7.00 per share. The case, Nkamga v. Paragon Therapeutics, Inc., is pending in the United States — United States District Court for the Southern District of California. ClaimsFiler is reminding investors of the September 28, 2026 lead plaintiff deadline.

Key Actions
100 United States — Food and Drug Administration denied Biologics License Application Paragon Therapeutics
100 Paragon Therapeutics stock dropped
80 Kahn Swick & Foti filed class action lawsuit Paragon Therapeutics
Entities Involved
priv
Paragon Therapeutics
Capricor is the defendant in the securities class action and the subject of FDA criticism over its statistical analysis plan. The stock fell 64% following the FDA briefing documents, and the company faces legal and regulatory challenges that threaten its lead product candidate.
Importance 100.0 Sentiment -90.0
govactor
United States — Food and Drug Administration
The FDA published briefing documents that criticized Capricor's post-hoc SAP changes, leading to the stock decline. The FDA's advisory committee review of Deramiocel is central to the event, and its findings have significant implications for Capricor's regulatory approval.
Importance 80.0 Sentiment 0.0
priv
Kahn Swick & Foti
The law firm filed the securities class action lawsuit against Capricor on behalf of investors. It is actively soliciting lead plaintiffs and providing legal representation, playing a key role in the litigation.
Importance 60.0 Sentiment 0.0
govactor
United States — United States District Court for the Southern District of California
The court is where the securities class action lawsuit is pending. Its rulings will determine the course of the litigation and potential recovery for investors.
Importance 40.0 Sentiment 0.0
Relationships
Paragon Therapeutics related ↔ United States — Food and Drug Administration
United States — Food and Drug Administration related ↔ Kahn Swick & Foti
Kahn Swick & Foti related ↔ United States — United States District Court for the Southern District of California
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.